Showing results (1-10 of 85) with videos related to
Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|August 15, 2021
Dissecting the biological heterogeneity of HER2-positive breast cancerFrancesco Schettini, Aleix PratHeliyon|January 1, 2024
Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectivesFrancesco Schettini, Fabiola Giudici, Daniele GeneraliCurrent Opinion in Oncology|August 24, 2022
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatmentIsabel Garcia-Fructuoso, Raquel Gomez-Bravo, Francesco SchettiniCancer Treatment Reviews|September 26, 2016
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectivesFrancesco Schettini, Mario Giuliano, Sabino De Placido, et al.Cancer Treatment Reviews|December 23, 2022
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancerClaudette Falato, Francesco Schettini, Tomás Pascual, et al.Critical Reviews in Oncology/Hematology|September 21, 2024
Reawakening the master switches in triple-negative breast cancer: A strategic blueprint for confronting metastasis and chemoresistance via microRNA-200/205: A systematic reviewArmia Ahmadi-Hadad, Paula Catarina Carvalho de Queiroz, Francesco Schettini, et al.Cancer Treatment Reviews|April 9, 2016
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are goingFrancesco Schettini, Giuseppe Buono, Cinzia Cardalesi, et al.Breast Care (Basel, Switzerland)|December 14, 2017
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?Francesco Schettini, Giuseppe Buono, Meghana V Trivedi, et al.Anti-Cancer Agents in Medicinal Chemistry|November 8, 2017
The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?Giuseppe Buono, Francesco Schettini, Francesco Perri, et al.Annals of Surgical Oncology|February 22, 2023
Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model ProposalIsaac Cebrecos, Eduard Mension, Inmaculada Alonso, et al.Pageof 9